Curriculum Vitae
David J. Riese II

I. PERSONAL INFORMATION

HOME ADDRESS 5302 Golden Sedge Place, Auburn, AL 36830
TELEPHONE 334-844-8358 (O) 334-750-0947 (M)
BIRTH DATE 11 April 1965 BIRTHPLACE Sheboygan, WI

II. EDUCATION

A.B. *Summa Cum Laude* (Biology), Wabash College, 1987
M.Phil. (Human Genetics), Yale University School of Medicine, 1989
Ph.D. (Genetics), Yale University School of Medicine, 1993
Postdoctoral Fellowship (Pathology), Yale University School of Medicine, 1993-1995

III. GENERAL INFORMATION

A. Academic Appointments:

Postdoctoral Fellow, Department of Pathology, Yale University School of Medicine, 1993-1995
Associate Research Scientist, Department of Pathology, Yale University School of Medicine, 1995-1997
Assistant Professor, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, 1997-2003
Associate Professor (Tenured), Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, 2003-2010
Adjunct Professor, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, 2010-2018
Associate Dean for Research and Graduate Programs, Auburn University Harrison School of Pharmacy, 2010-2018.
Gilliland Professor, Department of Drug Discovery and Development, Auburn University Harrison School of Pharmacy, 2010-present.

B. Awards and Honors:

A.B. Summa Cum Laude, Phi Beta Kappa, Wabash College, 1987
Predoctoral Fellowship, Howard Hughes Medical Institute, 1988-1993
Postdoctoral Fellowship, U.S Army Medical Research and Materiel Command (USAMRMC) Breast Cancer Research Program (BCRP), 1994-1997
Eliot C. Williams Alumnus Prize in Biology, Wabash College, 1998
Henry W. Heine Memorial Award for Excellence in Undergraduate Teaching, Purdue University College of Pharmacy, 2000
Career Development Award, USAMRMC BCRP, 2000-2004
New Investigator Award, USAMRMC Prostate Cancer Research Program, 2002-2005
Outstanding Cancer Research Award, Purdue University Center for Cancer Research and Lafayette (IN) Lions Club, 2010
Westfield (Indiana) High School Alumni Hall of Fame, 2011
Fellow, American Association of Colleges of Pharmacy (AACP) Academic Leadership Fellows Program (ALFP), 2011-2012
Auburn University President's Outstanding Collaborative Units Award – The Pharmaceutical Engineering Team, 2014

C. Memberships in Academic, Professional, and Scholarly Societies:

American Association for Advancement of Science, American Association for Cancer Research, American Association of Colleges of Pharmacy, American Association of Pharmaceutical Scientists, American Chemical Society, American Society for Microbiology, American Society of Biochemistry and Molecular Biology, Sigma Xi Scientific Fraternity, Kappa Psi Pharmaceutical Fraternity, Phi Beta Kappa Liberal Arts and Sciences Honorary Fraternity

IV. RESEARCH INTERESTS

OVERVIEW – We study the Epidermal Growth Factor (EGF) family of peptide hormones and their receptors, the ErbB receptor tyrosine kinases. This network regulates the proliferation and differentiation of epithelial cells and deregulated signaling by this network contributes to human tumorigenesis and increased tumor cell invasiveness, metastatic potential, and chemoresistance. Consequently, we seek to understand the mechanism by which this network regulates cell function, with the ultimate goal being the development of novel cancer treatments. Citations in the following paragraphs refer to Section V of my CV.

ERBB4 AND EPITHELIAL TUMORS – Activating (gain-of-function) mutations in ErbB4 are observed in a variety of epithelial tumors, indicating that ErbB4 functions as an oncogene. On the other hand, ErbB4 expression is lost in some types of epithelial tumors, indicating that ErbB4 is coupled to tumor suppression. Thus, we are using various expression systems, analytical approaches, ErbB4 ligands, and ErbB4 mutants to characterize ErbB4 coupling to tumor suppression and malignant phenotypes [19, 25, 26, 41, 44, 50]. We are focused on deciphering the mechanisms by which ErbB4 can be coupled to these divergent responses [13, 25, 26, 31, 32, 41, 43, 44, 50, 53]. We are also pursuing the discovery and development of novel ErbB4 agonists and antagonists that can be used to pharmacologically probe ErbB4 function in human malignancies and hold potential for the treatment of ErbB4-dependent tumors [30, 36, 42, 46].

EGF FAMILY HORMONES - In collaboration with investigators throughout the world we are characterizing the biological activities of EGF family hormones and we are identifying factors that regulate the affinity, potency, and efficacy of these peptide growth factors [13, 17, 20, 21, 23, 24, 29, 30, 32, 34, 36, 39, 40, 42, 43, 45, 46, 48, 51, 52]. We are also interested in elucidating the structural features of EGF family hormones that are responsible for differences in affinity, potency, and efficacy (intrinsic activity).

V. PUBLICATIONS

A. Peer-Reviewed Journal Articles (of 53 reported by NCBI My Bibliography)

PubMed Search Results
ORCID Profile
~5000 Google Scholar citations; i10-Index = 47; H-Index = 33; (as of 02/2020)
#Indicates publication that contributes to i10-Index
***Indicates publication that contributes to H-index**

#*1. DJ Riese II, J Settleman, K Neary, and D DiMaio. Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity. *J Virology* **64**: 944-949 (1990). PMID: 2153255. Personal Copy.

#*2. C Leptak, S Ramon y Cajal, R Kulke, BH Horwitz, DJ Riese II, GP Dotto, and D DiMaio. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. *J Virology* **65**: 7078-7083 (1991). PMID: 1658398. Personal Copy.

3. JK Selkirk, BK Mansfield, DJ Riese, A Nikbakht, and RC Mann. Two-dimensional gel electrophoretic comparison of cytoplasmic proteins in C3H10T1/2 cells, a chemically-transformed 10T1/2 line, and a transformation resistant C3H mouse ventral prostate cell line. *Appl Theoret Electrophoresis* **2**: 43-51 (1991). PMID: 1932209.

#*4. ES Hwang, DJ Riese II, J Settleman, LA Nilson, J Honig, S Flynn, and D DiMaio. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. *J Virology* **67**: 3720-3729 (1993). PMID: 8389903. Personal Copy.

#*5. DJ Riese II, TM van Raaij, GD Plowman, GC Andrews, and DF Stern. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. *Mol Cell Biol* **15**: 5770-5776 (1995). PMID: 7565730. Personal Copy.

#*6. DJ Riese II and D DiMaio. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. *Oncogene* **10**: 1431-1439 (1995). PMID: 7731695.

#*7. DJ Riese II, Y Bermingham, TM van Raaij, S Buckley, GD Plowman, and DF Stern. Betacellulin activates the epidermal growth factor receptor and erbB4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. *Oncogene* **12**:345-353 (1996). PMID: 8570211.

#*8. DJ Riese II, ED Kim, K Elenius, S Buckley, M Klagsbrun, GD Plowman, and DF Stern. The epidermal growth factor receptor couples transforming growth factor alpha, amphiregulin, and heparin-binding EGF-like growth factor to neu, erbB3, and erbB4. *J Biol Chem* **271**: 20047-20052 (1996). PMID: 8702723. Personal Copy.

#*9. S Kannan, M De Santis, M Lohmeyer, DJ Riese II, GH Smith, N Hynes, M Seno, R Brandt, C Bianco, G Persico, N Kenney, N Normanno, I Martinez-Lacaci, F Ciardiello, DF Stern, WJ Gullick, and D Salomon. Cripto enhances the tyrosine phosphorylation of shc and activates map-kinase in mammary epithelial cells. *J Biol Chem* **272**: 3330-3335 (1997). PMID: 9013573. Personal Copy.

#*10. H Chang, DJ Riese II, W Gilbert, DF Stern, and UJ McMahan. Ligands for erbB family receptors encoded by a newly characterized neuregulin-like gene. *Nature* **387**: 509-512 (1997). PMID: 9168114. Personal Copy.

#*11. DJ Riese II and DF Stern. Specificity within the EGF family/ErbB receptor family signaling network. *Bioessays* **20**: 41-48 (1998). PMID: 9504046. Personal Copy.

#*12. DJ Riese II, T Komurasaki, GD Plowman, and DF Stern. Activation of ErbB4 by the bifunctional EGF family hormone epiregulin is regulated by ErbB2. *J Biol Chem* **273**: 11288-11294 (1998). PMID: 9556621. Personal Copy.

#*13. C Sweeney, C Lai, DJ Riese II, AJ Diamonti, LC Cantley, and KL Carraway III. Ligand discrimination in signaling through an ErbB4 receptor homodimer. *J Biol Chem* **275**: 19803-19807 (2000). PMID: 10867024. Personal Copy.

#*14. F Mu, SL Coffing, DJ Riese II, RL Geahlen, P Verdier-Pinard, E Hamel, J Johnson, and M Cushman. Design, synthesis, and biological evaluation of a series of Lavendustin A analogs which inhibit EGFR and Lck tyrosine kinases, as well as tubulin polymerization. *J Med Chem* **44**: 441-452 (2001). PMID: 11462983. Personal Copy.

#15. K Feroz, EE Williams, and DJ Riese II. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. *Cell Signal* **14***:* 793-798 (2002). PMID: 12034361. Personal Copy.

#*16. DJ Penington, I Bryant, and DJ Riese II. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. *Cell Growth Differ* **13**: 247-256 (2002). PMID: 12114214. Personal Copy.

#*17. SS Hobbs, SL Coffing, ATD Le, EM Cameron, EE Williams, M Andrew, EN Blommel, RP Hammer, H Chang, and DJ Riese II. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. *Oncogene* **21**: 8442-8452 (2002). PMID: 12466964. Personal Copy.

#*18. J Walker-Daniels, DJ Riese II, and MS Kinch. c-Cbl dependent EphA2 protein degradation is induced by ligand binding. *Mol Cancer Res* **1**: 79-87 (2002). PMID: 12496371. Personal Copy.

#*19. EE Williams, LJ Trout, RM Gallo, SE Pitfield, DJ Penington, I Bryant, and DJ Riese II. A constitutively-active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. *Cancer Lett* **192**: 67-74 (2003). PMID: 12637154. Personal Copy.

#20. SS Hobbs, EM Cameron, RP Hammer, ATD Le, RM Gallo, EN Blommel, SL Coffing, and DJ Riese II. Five carboxyl-terminal residues of Neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. *Oncogene* **23**: 883-894 (2004). PMID: 14661053. Personal Copy.

#21. JL Gilmore and DJ Riese II. secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. *Oncol Res* **14**: 589-602 (2004). PMID: 15667000. Personal Copy.

#*22. HF VanBrocklin, JK Lim, SL Coffing, DL Hom, K Negash, MY Ono, SM Hanrahan, SE Taylor, JL Gilmore, I Bryant, and DJ Riese II. Anilino-dialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. *J Med Chem* **48**: 7445-7456 (2005). PMID: 16279804. Personal Copy.

23. SS Hobbs, RM Gallo, and DJ Riese II. Phe45 of NRG2β is critical for the affinity of NRG2β for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2β. *Growth Factors* **23**: 273-283 (2005). PMID: 16338790. Personal Copy.

#*24. JL Gilmore, RM Gallo, and DJ Riese II. The EGFR-S442F mutant displays increased affinity for Neuregulin2β and agonist-independent coupling to downstream signaling events. *Biochem J* **396**: 79-88 (2006). PMID: 16445385. Personal Copy.

#25. RM Gallo, I Bryant, R Fry, EE Williams, and DJ Riese II. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. *Biochem Biophys Res Com* **349**: 372-382 (2006). PMID: 16934755. Personal Copy.

#26. SE Pitfield, I Bryant, DJ Penington, G Park, and DJ Riese II. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. *Oncol Res* **16**: 179-193 (2006). PMID: 17120616. Personal Copy.

#*27. DJ Riese II, RM Gallo, and J Settleman. Mutational activation of ErbB receptor tyrosine kinases: Insights into mechanisms of signal transduction and tumorigenesis. *Bioessays* **29:** 558-565 (2007). PMID: 17508401. Personal Copy.

#*28. N Godin-Heymann, I Bryant, MN Rivera, L Ulkus, DW Bell, DJ Riese II, J Settleman, and DA Haber. Oncogenic activity of EGFR kinase mutant alleles is enhanced by the T790M drug resistance mutation. *Cancer Res* **67**: 7319-7326 (2007). PMID: 17671201. Personal Copy.

#*29. JL Gilmore, JA Scott, Z Bouizar, A Robling, SE Pitfield, DJ Riese II, and J Foley. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. *Breast Cancer Res Treat* **110**: 493-505 (2008). PMID: 17882547. Personal Copy.

#30. KJ Wilson, CP Mill, EM Cameron, SS Hobbs, RP Hammer, and DJ Riese II. Interconversion of Neuregulin2 full and partial agonists for ErbB4. *Biochem Biophys Res Com* **364**: 351-357 (2007). PMID: 17945187. Personal Copy.

31. RM Gallo and DJ Riese II. The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine 1056. *Growth Factors* **25**: 329-333 (2007). PMID: 18236211. Personal Copy.

#*32. T Frogne, RV Benjaminsen, K Sonne-Hansen, BS Sorensen, E Nexo, A-V Laenkholm, LM Rasmussen, DJ Riese II, P de Cremoux, J Stenvang, and AE Lykkesfeldt. Activation of ErbB3, EGFR, and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. *Breast Cancer Res Treat* **114**: 263-275 (2009). PMID: 18409071. Personal Copy.

#*33. SM Rothenberg, JA Engelman, S Le, DJ Riese II, DA Haber, and J Settleman. Modeling oncogene addiction with RNA interference. *Proc Natl Acad Sci USA* **105**: 12480-12484 (2008). PMID: 18711136. Personal Copy.

#*34. NE Willmarth, A Baillo, ML Dziubinski, K Wilson, DJ Riese II, and SP Ethier. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. *Cell Signal* **21**: 212-219 (2009). PMID: 18951974. Personal Copy.

#35. JA Przybyla, JP Cueva, BR Chemel, KJ Hsu, DJ Riese II, JD McCorvy, JA Chester, DE Nichols, and VJ Watts. Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors. *Eur Neuropsychopharmacol* **19**: 138-146 (2009). PMID: 19028082. Personal Copy.

#*36. KJ Wilson, JL Gilmore, J Foley, MA Lemmon, and DJ Riese II. Functional selectivity of EGF Family Peptide Growth Factors: Implications for Cancer. *Pharmacol Ther* **122**: 1-8 (2009). PMID: 19135477. Personal Copy.

#*37. CP Mill, JA Chester, and DJ Riese II. EGFR may couple moderate alcohol consumption to increased breast cancer risk. *Breast Cancer – Targets and Therapy (London)* **1**: 31-38 (2009). PMID: 20485537. Personal Copy.

#*38. BG Coon, D Mukherjee, CB Hanna, DJ Riese II, M Lowe, and RC Aguilar. Lowe syndrome patient fibroblasts display Ocr11-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. *Hum Mol Gen* **18**: 4478-4491 (2009). PMID: 19700499. Personal Copy.

#39. JL Gilmore, RM Gonterman, K Menon, G Lorch, DJ Riese II, A Robling, and J Foley. Reconstitution of amphiregulin-EGFR signaling in lung squamous carcinomas activates PTHrP gene expression and cancer-mediated diseases of the bone. *Mol Cancer Res* **7**: 1714-1728 (2009). PMID: 19825997. Personal Copy.

#*40. J Foley, NK Nickerson, S Nam, KT Allen, JL Gilmore, KP Nephew, and DJ Riese II. EGFR signaling in breast cancer: Bad to the bone? *Sem Cell Dev Biol* **21**: 951-960 (2010). PMID 20813200. Personal Copy.

#41. CP Mill, K Gettinger, and DJ Riese II. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. *Exp Cell Res* **317**: 392-404 (2011). PMID: 21110957. Personal Copy.

#42. DJ Riese II. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? *Expert Opin Drug Disc* **6**: 185-193 (2011). PMID: 21532939. Personal Copy.

#*43. MD Zordan, CP Mill, DJ Riese II, and JF Leary. A high-throughput, interactive imaging, bright-field wound healing assay. *Cytometry A* **79A**: 227-232 (2011). PMID: 22045642. Personal Copy.

#44. CP Mill, MD Zordan, SM Rothenberg, J Settleman, JF Leary, and DJ Riese II. ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer. *Genes & Cancer* **2**: 792-804 (2011). PMID: 22393464. Personal Copy.

#*45. KJ Wilson, CP Mill, S Lambert, J Buchman, TR Wilson, V Hernandez-Gordillo, RM Gallo, Laura MC Ades, J Settleman, and DJ Riese II. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. *Growth Factors* **30**: 107-116 (2012). PMID: 22260327. Personal Copy.

46. KJ Wilson, CP Mill, RM Gallo, EM Cameron, H VanBrocklin, J Settleman, and DJ Riese II. The Q43L mutant of Neuregulin 2beta is a pan-ErbB receptor antagonist. *Biochem J* **443**: 133-144 (2012). PMID: 22216880. Personal Copy.

#47. J Foley, NK Nickerson, DJ Riese II, PC Hollenhorst, G. Lorch, and AM Foley. At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of the bone. *Odontology* **100**: 109-129 (2012). PMID: 22684584. Personal Copy.

#48. NK Nickerson, CP Mill, HJ Wu, DJ Riese II, and J Foley. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. *Oncol Res* **20**: 303-17 (2013). PMID: 23879171. Personal Copy.

#*49. RE Allen, J Copeland, AS Franks, R Karimi, M McCollum, DJ Riese II, and AYF Lin. Team-based learning in US colleges and schools of pharmacy. *Am J Pharm Ed* **77**: 115 (2013). PMID: 23966718. Personal Copy.

50. RM Gallo, IN Bryant, CP Mill, S Kaverman, and DJ Riese II. Multiple functional motifs are required for the tumor suppressor activity of a constitutively-active ErbB4 mutant. *J Cancer Res Ther Oncol* **1**: 104 (2013). PMID: 24791013. Personal Copy.

#*51. DJ Riese II and RL Cullum. Epiregulin: Roles in Normal Physiology and Cancer. *Sem Cell Dev Biol*. **28**: 49-56 (2014). PMID 24631357. Personal Copy.

52. SP Kanthala, CP Mill, DJ Riese II, M Jaiswal, and SD Jois. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. *Protein Expr Purif* **25**: (01) 26-33 (2016). PMID: 26363121. Personal Copy.

#53. FML Kabir, P DeInnocentes, P Agarwal, CP Mill, DJ Riese II, and RC Bird. Estrogen Receptor-alpha, Progesterone Receptor and c-erbB/HER-Family Receptor mRNA Detection and Phenotype Analysis in Spontaneous Canine Models of Breast Cancer. *Journal of Veterinary Science* **18**: (02) 149-158 (2017). PMID: 27515268. Personal Copy.

B. Book Chapters (of 4 total)

BC1. JK Selkirk, BK Mansfield, DJ Riese II, A Nikbakht, and RC Mann. "Two-dimensional gel electrophoresis of cytoplasmic proteins in control and transformed 10T1/2 and CVP cells after benzo[a]pyrene treatment." In: Multilevel health effects research: From Molecules to Man: *Proceedings of the Twenty-Seventh Hanford Life Sciences Symposium*, JF Park and RA Pelroy, eds. Batelle Press, Columbus, OH (1988). ISBN: 09-3547-055-7.

BC2. LA Nilson, LM Petti, D Drummond-Barbosa, DJ Riese II, ES Hwang, T Nottoli, C Henningson Jr, GW Polack, DM Kegler-Ebo, and D DiMaio. "The role of the cellular platelet-derived growth factor receptor in cell transformation by the bovine papillomavirus E5 protein." In: *Current Developments in Animal Virology*, S Jameel and EK Wagner, eds. Science Publishers (1996). ISBN: 18-8610-661-4.

BC3. RM Gallo and DJ Riese II. "Activating Mutations of ErbB Family Receptor Tyrosine Kinases." In: *Recent Progress in Cancer Research*, C.K. Tang, ed. Transworld Research Network, Kerala, India (2007). ISBN: 81-7895-253-X. Personal Copy.

BC4. NK Nickerson, JL Gilmore, KT Allen, DJ Riese II, KP Nephew and J Foley. "EGFR Ligand-Specific Signaling in Breast Cancer Metastasis: Recurring Developmental Themes." In: *Breast Cancer – Carcinogenesis, Cell Growth, and Signalling Pathways*, Mehmet Gunduz and Esra Gunduz, eds. Intech Publishing, Rijeka, Croatia (2011). ISBN: 978-953-307-714-7. Personal Copy.

VI. PRESENTATIONS (2017-present)

"Getting Academic Works Published in Peer-Reviewed Journals." Auburn University Graduate School, February 2017. PowerPoint Slides.

"University of South Alabama Graduate School: Vision and Goals." University of South Alabama, April 2017. PowerPoint Slides.

"Getting Published in Peer-Reviewed Journals." Auburn University Graduate School, September 2017. PowerPoint Slides.

"Report of the Associate Dean for Research and Graduate Programs." Auburn University Harrison School of Pharmacy Dean's Advisory Council meeting, October 2017. PowerPoint Slides.

"Getting Published in Peer-Reviewed Journals." Auburn University Graduate School, June 2018. PowerPoint Slides.

"Getting Published in Peer-Reviewed Journals." Auburn University Graduate School, September 2018. PowerPoint Slides.

"Auburn University Health Sciences Research Initiative." Alabama Cooperative Extension System, October 2018. PowerPoint Slides.

"Publishing in Peer-Reviewed Journals." Auburn University Graduate School, February 2019. PowerPoint Slides.

"Auburn University Health Sciences Research Initiative." Auburn University Research and Economic Development Advisory Board Meeting, May 2019. PowerPoint Slides.

"Cancer Drug Discovery and Development Research in the Department of Drug Discovery and Development." Visit by the Auburn University Vice President for Research and Economic Development, July 2019. PowerPoint Slides.

"What the Research Administrator Needs to Know About Biologicals" National Council of University Research Administrators Annual Meeting, August, 2019 (with Ianthe Bryant-Gawthrop, Auburn University). PowerPoint Slides.

"Vision for Advancing Research and Innovation at the Texas Tech University Health Sciences Center." Texas Tech University Health Sciences Center, January, 2020. PowerPoint Slides.

VII. ABSTRACTS & POSTERS (2017-present)

RL Cullum, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese II. "Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase." American Association for Cancer Research Annual Meeting, Washington, DC, April 2017. Abstract Poster

RL Cullum, JI Senfeld, JT Piazza, LT Neel, RB Gupta, AE David, DJ Riese II. "Screening methodologies for the discovery of targeted melanoma therapeutics." Auburn University "This is Research" Student Research Symposium, April 2017. Abstract Poster

RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese II. "Characterization of putative ErbB4 antagonists: Targeted melanoma drug discovery." Auburn University Research Initiative in Cancer Annual Meeting, August 2017. Poster

RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese II. "Characterization of putative ErbB4 antagonists: Targeted melanoma drug discovery." AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, October 2017. Abstract Poster

LM Lucas, RL Cullum, JI Senfeld, MH Harris, JT Piazza, LT Neel, RB Gupta, AE David, and DJ Riese II. "Characterization of selective and non-selective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics." Auburn University "This is Research" Student Research Symposium, March 2018. Poster

LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, CC Rael, DC Taylor, JT Piazza, LT Neel, RB Gupta, AE David, and DJ Riese II. "Characterization of selective and non-selective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics." Auburn University Research Initiative in Cancer Annual Meeting, August 2018. Poster

RL Cullum, TM Ghosh, LM Lucas, and DJ Riese II. "Identification of candidate melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene." Auburn University Research Initiative in Cancer Annual Meeting, August 2018. Poster

LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, CC Rael, DC Taylor, JT Piazza, LT Neel, RB Gupta, AE David, and DJ Riese II. "Characterization of selective and non-selective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics." Melanoma: From Biology to Target, an American Association for Cancer Research Melanoma Meeting, Houston, TX, January 2019. Poster

RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, and DJ Riese II. "Mutations in ERBB4 may account for clinical resistance of melanoma to inhibitors of the RAS/RAF/MEK/MAPK pathway." Melanoma: From Biology to Target, an American Association for Cancer Research Melanoma Meeting, Houston, TX, January 2019. Poster

RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, and DJ Riese II. " "Mutations in ERBB4 may account for clinical resistance of melanoma to inhibitors of the RAS/RAF/MEK/MAPK pathway." American Association for Cancer Research Annual Meeting, Atlanta, GA, April 2019. Poster

VIII. GRANT SUPPORT

A. As Principal Investigator – *See www.davidriese.com/funding-history*

"Growth Transformation by Papillomavirus Genes"
Howard Hughes Medical Institute Predoctoral Fellowship in Genetics
David J. Riese II, PI — 06/01/88 – 05/31/93
$ 150,000 total direct costs

"Heregulin-Induced Growth Receptor Signaling and Breast Carcinogenesis"
USAMRMC Breast Cancer Research Program Postdoctoral Fellowship — BC930291
David J. Riese II, PI — 07/01/94 – 06/30/97
$ 123,719 total direct costs

"*Studies of the ErbB4 Receptor Tyrosine Kinase*"
Showalter Trust
David J. Riese II, PI — 07/01/98 – 06/30/99
$ 45,200 total direct costs

"*Inhibition of Breast Tumor Cell Line Proliferation, Motility, and Invasiveness*"
National Institutes of Health/National Cancer Institute — R21CA080770
David J. Riese II, PI — 04/01/99 – 03/31/01
$ 150,000 total direct costs

"Functional Analysis of the ErbB4 Receptor Tyrosine Kinase"
USAMRMC Breast Cancer Research Program — BC990107
David J. Riese II, PI — 07/01/00 – 06/30/03
$ 216,000 total direct costs

"Tumor Imaging Agents Directed Against ErbB2"
National Institutes of Health/National Cancer Institute — R21CA089274
David J. Riese II, PI — 07/01/01 – 06/30/04
$ 200,000 total direct costs

"Functional Analysis of the ErbB4 Receptor Tyrosine Kinase"
USAMRMC Breast Cancer Research Program — BC990790
David J. Riese II, PI — 07/01/00 – 06/30/04
$ 132,000 total direct costs

"*Regulation of Prostate Tumor Cell Line Proliferation and Tumorigenicity by the ErbB4 Receptor Tyrosine Kinase*"
USAMRMC Prostate Cancer Research Program — PC010077
David J. Riese II, PI — 02/01/02 – 01/31/05
$ 225,000 total direct costs

"*Mechanism by Which Parkinson's Disease Patients Exhibit an Elevated Risk of Breast Cancer*"
Showalter Trust 670-1333-7310
David J. Riese II, PI; Val J. Watts, co-PI 07/01/05 – 12/31/06
$ 62,500 total direct costs

"*Synthesis and Evaluation of Targeted Cancer Chemotherapeutic Nanotubes*"
Purdue School of Pharmacy Lilly Endowment Seed Grant Program
David J. Riese II, PI; Donald Bergstrom, co-PI 01/01/08 – 12/31/08
$75,000 total costs (Riese lab direct costs = $25,000)

"*Instructional Equipment Grant*"
Purdue School of Pharmacy Program
David J. Riese II, PI 01/01/09 – 12/31/09
$4,000 total direct costs

"*Instructional Equipment Grant*"
Purdue School of Pharmacy Program
David J. Riese II, PI 06/01/10 – 12/31/10
$6,400 total direct costs

"Regulation of ErbB4 Signaling by Neuregulin Isoforms"
National Institutes of Health/National Cancer Institute R01CA114209
David J. Riese II, PI; Mark A. Lemmon, UPenn, subcontractor 08/01/06 – 07/31/12
$ 1,241,777 total costs (Riese lab direct costs = $607,980)

"Validation of Canine Models for Human Breast Cancer"
Auburn University Office of Vice President for Research IGP
David J. Riese II, PI; Curtis Bird, COVM, co-PI 01/01/11 – 12/31/12
$35,062 total direct costs

"Development of HTS Assays for ErbB4 Partial Agonists and Antagonists"
Auburn University Research Initiative in Cancer (AURIC)
David J. Riese II, PI 01/01/14 – 12/31/14
$100,000 total costs ($100,000 direct costs)

B. As Co-investigator – *See www.davidriese.com/funding-history*

"Binding determinants of Neuregulin to the ErbB4 receptor"
National Institutes of Health/National Cancer Institute F33CA085049
Robert P. Hammer, Louisiana State University, PI
David J. Riese II, mentor 03/15/00 – 03/14/01
$ 46,300 total costs (stipend for Dr. Hammer)

"*A Summer Undergraduate Training Program in Breast Cancer Research*"
USAMRMC Breast Cancer Research Program DAMD17-02-1-0555
G. Marc Loudon, Purdue University, PI
David J. Riese II, co-PI 05/01/02 – 04/30/06
$ 141,000 total costs ($0 total direct costs for the Riese laboratory)

"Targeted Molecular Probes for Tumor Imaging"
National Institutes of Health/National Cancer Institute R01CA094253
Henry VanBrocklin, Lawrence Berkeley National Laboratory, PI
David J. Riese II, co-PI 09/01/02 – 08/31/06
$ 1,547,739 total costs ($ 240,000 total direct costs for the Riese laboratory)

"Gefitinib-Sensitive EGF Receptor Mutants in Lung Cancer"
National Institutes of Health/National Cancer Institute R01CA115830
Jeffrey Settleman, Massachusetts General Hospital/Harvard Medical School, PI
David J. Riese II, co-PI 06/01/05 – 04/30/10
$ 2,978,883 total costs ($ 200,000 total direct costs for the Riese laboratory)

"*Leap Image Scanning Cytometer/Sorter/Optoinjection Shared Instrument"*
National Institutes of Health S10RR023651
James Leary, Purdue, PI
David J. Riese II, co-PI 01/07/10 – 01/06/11
$ 495,000 total costs ($ 0 total direct costs for the Riese laboratory)
As co-PI, Dr. Riese assisted in the preparation of this equipment grant application. Moreover, Dr. Riese was a major user of the aforementioned LEAP instrument and the acquisition of this instrument led to two publications with James Leary.

"Cancer Center Support Grant"
National Institutes of Health/National Cancer Institute P30CA023168
Timothy Ratliff, Purdue University Center for Cancer Research Director and PI
David J. Riese II, Center for Cancer Research co-Program Leader and co-PI 09/08/10 – 06/30/15
$ 6,407,190 total costs ($ 0 total direct costs for the Riese laboratory)
As co-PI, Dr. Riese assisted in the preparation of the application (and in the site visit) that led to the competitive renewal of this award beyond award year 29 (June 2010). Moreover, Dr. Riese was a co-program leader of the Purdue University Center for Cancer Research, which was supported by this P30 grant. However, note that Dr. Riese is no longer affiliated with the Purdue University Center for Cancer Research or this award.

"Graduate Assistance in the Areas of National Need (GAANN): Fellowships in Biological and Pharmaceutical Engineering" P200A120244
United States Department of Education N/A
ME Byrne, AU Department of Chemical Engineering, PI
David J. Riese II, investigator/mentor 08/01/12 – 07/31/15
$ 824,532 total costs (funds supported a GRA shared by David Riese's laboratory and Allan David's laboratory)

IX. RESEARCH MENTORING ACTIVITIES

A. Graduate Student Thesis/Dissertation Advisor (10 total)

1. Current (2):

Cullum, Richard (Auburn University Chemical Engineering, PhD anticipated 2020)

Lucas, Lauren (Auburn University Pharmaceutical Sciences, PhD anticipated 2022)

2. Previous (8):

Penington, Desi (Purdue University BMB; M.S., 2001). Thesis title: "Construction and analysis of constitutively-active mutants of the ErbB4 receptor tyrosine kinase." Current status: Physician, Denver, Colorado. Thesis research published in a 2002 paper in *Cell Growth and Differentiation*, in a 2003 paper in *Cancer Letters*, and in a 2006 paper in *Oncology Research*.

Hobbs, Stuart (Purdue University BMB; Ph.D., 2005). Dissertation title: "The basis of ErbB4 ligand specificity." Current status: Officer and Staff Scientist, United States Army. Dissertation research published in 2002 and 2004 papers in *Oncogene,* a 2005 paper in *Growth Factors*, and a 2007 paper in *Biochemical and Biophysical Research Communications*.

Gilmore, Jennifer (Purdue University MCMP; Ph.D., 2005). Dissertation title: "Development of ErbB4 antagonists." Current status: Clinical Trial Manager, Pharmaceutical Product Development. Dissertation research published in a 2004 paper in *Oncology Research* and a 2006 paper in *Biochemical Journal*.

Pitfield, Sarah (Purdue University MCMP; M.S., 2006). Thesis title: "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines." Current status: Science teacher, Davis, California. Thesis research published in a 2006 paper in *Oncology Research* and a 2008 paper in *Breast Cancer Research and Treatment*.

Bryant-Gawthrop, Ianthe (Purdue University BMB; M.S., 2006). Thesis title: "Regulation of ErbB4 Tumor Suppression." Current status: Director of Research Regulatory Compliance, Purdue University. Thesis research published in a 2006 paper in *Oncology Research*, a 2007 paper in *Cancer Research*, and a 2013 paper in the *Journal of Cancer Research and Therapeutic Oncology*.

Gallo, Richard (Purdue University MCMP; Ph.D., 2007). Dissertation title: "ErbB4 Signal Transduction and Subcellular Localization During Prostate Tumor Suppression." Current status: Unknown. Dissertation research published in a 2003 paper in *Cancer Letters*, a 2004 paper in *Oncogene*, a 2005 paper in *Growth*

Factors, a 2006 paper in *Biochemical Journal*, a 2006 paper in *Biochemical and Biophysical Research Communications*, a 2007 paper in *Bioessays*, a 2007 paper in *Growth Factors*, a 2012 paper in *Biochemical Journal*, a 2012 paper in *Growth Factors*, and a 2013 paper in the *Journal of Cancer Research and Therapeutic Oncology*.

Wilson, Kristy (Purdue University BMB; Ph.D., 2009). Dissertation title: "EGF Family Hormones Stimulate Distinct Biological Responses: Implications for Tumorigenesis and Cancer Treatment." Current status: Assistant Professor, Marian University. Dissertation research published in a 2007 paper in *Biochemical and Biophysical Research Communications*, a 2009 paper in *Pharmacology and Therapeutics*, a 2009 paper in *Cell Signaling*, a 2012 paper in *Growth Factors*, and a 2012 paper in *Biochemical Journal*.

Mill, Christopher (Purdue University MCMP; Ph.D., 2011). Dissertation title: "The ErbB4 Receptor Tyrosine Kinase Couples to Divergent Biological Responses in a Context-Dependent Manner." Current status: Research Scientist, MD Anderson Cancer Center. Dissertation research published in a 2007 paper in *Biochemical and Biophysical Research Communications,* a 2009 paper in *Breast Cancer*, a 2011 paper in *Experimental Cell Research*, a 2011 paper in *Cytometry A*, a 2011 paper in *Genes and Cancer*, a 2012 paper in *Growth Factors*, a 2012 paper in *Biochemical Journal*, a 2013 paper in *Oncology Research*, a 2013 paper in *Journal of Cancer Research and Therapeutic Oncology*, a 2016 paper in *Protein Expression and Purification*, and a 2017 paper in *Journal of Veterinary Science*.

B. Graduate Student Thesis/Dissertation Advisory Committee

1. Current (1):

Smith, Warren (Drug Discovery and Development, Auburn University)

2. Past (25):

Ahyi, Nathalie (Purdue University; M.S. 2004). Thesis title: "Characterization of Geldanamycin as a potential antifungal for *Candida albicans*: Advantages over purine inhibitors"

Amin, Dhara (Yale University; Ph.D., 2003). Dissertation title: "Gene expression analysis of ErbB family signaling: Encodement of signaling specificity and identification of targets of ErbB2 and ErbB4."

Beazely, Michael (Purdue University; Ph.D., 2004). Dissertation title: "Novel regulatory properties of adenylate cyclase type 6."

Bhattacharya, Subrhajit (Auburn University; Ph.D., 2016). Dissertation title: "Glutamate receptor mediated bi-directional plasticity is responsible for reconsolidation of fear memories."

Bloemer, Jenna (Auburn University; Ph.D., 2019). Dissertation title: "Adiponectin alters hippocampal synaptic function: a mechanism for amelioration of synaptic deficits in a mouse model of Alzheimer's disease."

Cho, Nami (Purdue University; Ph.D., 2000). Dissertation title: "Engineering of a monoclonal antibody to a tumor associated NADH oxidase (tNOX), a putative cancer specific cell surface determinant."

Cumbay, Mehane (Purdue University; Ph.D., 2004). Dissertation title: "Characterization of novel regulatory properties of adenylate cyclase type nine."

Daniels, Natae Nash (Purdue University; M.S., 2002). Thesis title: "Identification of a novel region of Bin1 that is required for growth suppression in MCF7 breast carcinoma cells but not in MCF10A non-malignant breast epithelial cells. "

Day, Travis (Purdue University; Ph.D., 2001). Dissertation title: "The investigation of the histidine biosynthetic pathway for drug target validation in the pathogenic yeast *Candida albicans*."

Fox-Hiatt, Susan (Purdue University; Ph.D., 2008). Dissertation title: "Understanding AP-1 dimerization *in vivo*: Genetic and BiFC analysis of C. elegans FOS-1 and JUN-1 regulation of ovulation."

Handley, Misty (Purdue University; Ph.D., 2007). Dissertation title: "Localization and Function of Ras Isoforms in Jurkat T Cells."

Johansson, Carina (Purdue University; M.S. 2006). Non-thesis master's degree.

Johnson, Joanna Killingbeck (Purdue University; M.S., 2001). Thesis title: "The physical involvement of Bin1 in an Rb/E1a signaling pathway."

Kennedy, Michael (Purdue University; Ph.D., 2001). Dissertation title: "Folate-targeted imaging agents."

Morse, Brent (Purdue University; M.S., 2001). Thesis title: "The role of syk in propagation of antigen receptor mediated signals through the ITAM signaling complex."

Myers, Rebecca S. (Purdue University; Ph.D., 2004). Dissertation title: "Imidazole glycerol phosphate synthase: Structural and kinetic studies of a triad glutamine amidotransferase."

Mu, Fanrong (Purdue University; Ph.D., 2002). Dissertation title: "Design, synthesis, and biological evaluation of Lavendustin A analogs."

Nguyen, Chau (Purdue University; Ph.D., 2006). Dissertation title: "Dexras1 is a novel modulator of adenylyl cyclase."

Pradhan, Shantanu (Auburn University; Ph.D., 2016). Dissertation title: “Three-Dimensional Tissue-Engineered Cancer Models For Tumorigenic Studies and Drug-Testing Applications.”

Pratt, Rebecca (Purdue University; Ph.D., 2003). Dissertation title: “Signal transduction by the EphA2 tyrosine kinase.”

Sabados, Dawn (Purdue University; Ph.D., 2005). Dissertation title: "Autofluorescence of cell level metabolic activity and dependence on the microenvironment."

Sandey, Maninder (Auburn University; Ph.D., 2012). Dissertation title: “Elucidation of genomic structure, biological properties, and functional status of canine MDA-7 and its receptors”.

Shi, Guanglu (Purdue University; Ph.D., 2010). Dissertation title: “Using mouse models to dissect cellular lineages and the molecular mechanisms of pancreatic cancer.”

Shi, Zhichang (Purdue University; Ph.D., 2005). Dissertation title: "Establishment of an *in vitro* blood-cerebrospinal fluid barrier model to study the mechanism of Pb-induced brain barrier damage."

Trebley, Joseph P. (Purdue University; Ph.D., 2006). Dissertation title: "Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance."

C. Postdoctoral Fellow Research Supervisor (4 total)

Shukla, Shruti (March 2001-March 2002). Current status: Postdoctoral Research Associate, Purdue University College of Veterinary Medicine

Mill, Christopher (January 2011-December 2011). Current status: Research Scientist, MD Anderson Cancer Center

Agarwal, Payal (February 2012- January 2013). Current status: Postdoctoral Fellow, Auburn University College of Veterinary Medicine

Ghosh, Taraswi (October 2017-February 2018) co-mentored with Robert Arnold, Auburn University Department of Drug Discovery and Development)

D. Supervisor for Undergraduate Research Personnel (~60 total)

I have served as the mentor for more than 60 undergraduate/professional school research trainees. During the school year, these trainees receive academic credit for their research activities. During the summer, these trainees receive a stipend. These trainees have been integral, productive members of my research group. Indeed, fourteen different trainees are co-authors on at least one of my research publications and six of these fourteen are co-authors on at least two of my publications. Two former trainees are primary authors on a publication stemming from work performed in my laboratory. Former trainees have gone on to pursue graduate degrees, professional degrees, or postgraduate professional training at some of the finest academic institutions in the United States, including Washington University at St. Louis, Harvard, Stanford, Georgia Institute of Technology, University of Kansas, University of North Carolina, Rutgers, UT-Southwestern Medical Center at Dallas, Indiana University, Auburn University, and Purdue University.

E. Supervisor For Other Research Personnel (3 total)

Bryant-Gawthrop, Ianthe (January 2003-August 2003). *Research technician*. Current status: Director of Research Regulatory Compliance, Purdue University.

Coffing, Stephanie (October 1997-March 2000). *Research technician*. Current status: Research Technician, Pfizer Central Research, Groton, Connecticut.

Hammer, Dr. Robert P. (July 1999-July 2000). *Sabbatical leave fellow* (Louisiana State University). Current status: Group Leader, Peptide Chemistry, Ra Pharmaceuticals, Cambridge, MA.

X. RECOGNITION OF RESEARCH ACTIVITIES

A. Member of Grant Application Peer Review Panels (Bold indicates 2019 activities)

Member, USAMRMC Breast Cancer Research Program Peer Review Panels (2000-16)

***Chair*, USAMRMC Breast Cancer Research Program Peer Review Panel (2017-19)**

Member, USAMRMC Prostate Cancer Research Program Peer Review Panels (2002-04)

Ad Hoc Member, NIH Basic Mechanisms of Cancer Therapeutics (BMCT) Study Section (2006-07)

Member, Susan G. Komen for the Cure Peer Review Panels (2008-10)

Ad Hoc Member, Various NIH, NSF, and other local, national, and international peer review panels (2000-present) – **2019 activities included the Children’s Tumor Foundation grant program and the UAB Center for Clinical and Translational Sciences intramural grant programs and PDQ programs**

B. Reviewer for Tenure and Promotion

I have served as an external referee for eleven applicants for faculty tenure and/or promotion, including one each in 2013-2017.

C. Editorial Board/Editorial Advisory Panel Member

Advances in Biological Chemistry (2010-present)
Biochemical Journal (2006-2015)
Breast Cancer – Targets and Therapy (2008-present)
Heliyon (2019-present)
Journal of Cancer Research and Therapeutic Oncology (2013-present)

B. *Ad Hoc* Reviewer for Professional Journals (underlined items indicate 2019 activities)

American Journal of Pharmaceutical Education, Biochemical Pharmacology, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Bioscience Reports, Biotechniques, Biotechnology and Applied Biochemistry, BMC Cancer, BMC Cell Biology, BMC Developmental Biology, Breast Cancer Research and Treatment, British Journal of Cancer, Cancer Biomarkers, Cancer Research, Cancers, Cell Growth and Differentiation, Cell Research, Clinical Pharmacology & Biopharmaceutics, EMBO Journal, European Journal of Biochemistry, Experimental Cell Research, Expert Opinion in Drug Discovery, FASEB Journal, FEBS Letters, Growth Factors, Heliyon, Journal of Experimental Medicine, Journal of the National Cancer Institute, Journal of Pharmacology and Experimental Therapeutics, Journal of Pharmaceutical Sciences and Pharmacology, Molecular Cancer Therapeutics, Molecular Psychiatry, Molecular Systems Biology, Nature Medicine, Oncogene, Oncotarget, PLOS One, Proceedings of the National Academy of Sciences (USA), Science Signaling, Seminars in Cell and Developmental Biology

XI. TEACHING – 2012/13 to present

A. Auburn University (Bold indicates ongoing activities)

PYDI 5X90 (Pharmacy Practice Experience I-VI): Team co-mentor, Fall 2010-18; Spring 2011-19
DRDD 7000 **(Grant Writing)**: Course developer, course director and instructor (45 lecture hours/offering), Fall 2011-present
PYPD 9280 **(Integrated Learning Experience 9: Oncology)**: Section developer and instructor (5 lecture hours/offering), Fall 2019-present
PYPD 9980 **(Mentored PharmD Research)**: Course developer and instructor (30 hours/offering), every semester (Fall, Spring) since Fall 2019
DRDD 7960 **(Drug Discovery and Development)**: Instructor (1.5 hours/offering), Fall 2019-present
VBMS 7970 **(Cancer Biology)**: Course developer and instructor (6 hours/offering), Fall 2019-present
DRDD 7960 **(Cancer Pharmacology and Drug Discovery)**: Course developer, course director, and instructor (~25 hours/offering), Spring 2020-present

XII. TEACHING – Evaluations and Awards

A. 2000 Purdue University Henry W. Heine Memorial Award for Excellence in Undergraduate Teaching

B. Teaching and Course Evaluations – 2011/12 to present

AUBURN UNIVERSITY - DRDD 7000 (Grant Writing)

FALL 2011	Mean overall instructor score of 3.75 (4-point scale)
FALL 2012	Mean overall instructor score of 4.00 (4-point scale)
FALL 2013	Mean overall instructor score of 4.00 (4-point scale)
FALL 2014	Mean overall instructor score of 4.00 (4-point scale)
FALL 2015	Mean overall instructor score of 4.00 (4-point scale)
FALL 2016	Mean overall instructor score of 4.00 (4-point scale)
FALL 2017	Mean overall instructor score of 3.70 (4-point scale)
FALL 2018	Dr. Moore was evaluated; not Dr. Riese
FALL 2019	Mean overall instructor score of 4.00 (4-point scale)

XIII. AUBURN UNIVERSITY COMMITTEES – 2017 to present (Bold indicates ongoing activities)

Chair, Harrison School of Pharmacy Graduate Programs Committee (2010-18)
Chair, Harrison School of Pharmacy Space, Facilities, and Safety Committee (2014-17)
President/Vice President/Member **Auburn University chapter of the Phi Beta Kappa Liberal Arts and Sciences Honorary Fraternity (2013-present)**
Co-Chair, Auburn University Research Instrumentation Facility Steering Committee (2013-18)
Chair/Member, Harrison School of Pharmacy PharmD-PhD Steering Committee (2014-18)
Co-Chair, Auburn University Research Infrastructure Prioritization Task Force (2014-17)

Chair, Auburn University School of Nursing Associate Dean for Research Search Committee (2016-17)
Chair, Auburn University Department of Health Outcomes Research and Policy Department Head Search Committee (2017)
Chair/Member, Harrison School of Pharmacy ACPE Self-Study Team 5 (2018-19)
***Liaison,* Auburn University Health Sciences Research Initiative (HSRI) Steering Committee (2018-present)**
***Auburn University Faculty Representative,* National Academies Federal Demonstration Partnership (2014-present)**

Member, Harrison School of Pharmacy Strategic Planning Committee (2010-18)
Member, Harrison School of Pharmacy Executive Committee (2010-18)
Member, Associate Deans for Research Forum (2010-18)
Member, Graduate Liaison Group (2010-18)
Member, University Research Council (2010-18)
Member, Auburn University Research Initiative in Cancer Steering Committee (2012-18)
Member, Auburn University Faculty Outreach Council (2012-18)
Member, Harrison School of Pharmacy Master's Degree in Pharmaceutical Technology and Systems Task Force (2015-17)
Member, Harrison School of Pharmacy PRC Learning Community 3 (2017-2018)
***Member,* Harrison School of Pharmacy PRC Learning Community 5 (2018-present)**
Member, Auburn University Research Instrumentation Task Force (2018-19)
Member, Auburn University Research Space and Facilities Task Force (2018-19)

Version 96
Last update 2020-02-21